Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial

Barbora De Courten, Michaela Jakubova, Maximilian P J De Courten, Ivica Just Kukurova, Silvia Vallova, Patrik Krumpolec, Ladislav Valkovic, Timea Kurdiova, Davide Garzon, Silvia Barbaresi, Helena J. Teede, Wim Derave, Martin Krssak, Giancarlo Aldini, Jozef Ukropec, Barbara Ukropcova

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objective Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors. Methods In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 ± 8 years; body mass index 31 ± 4 kg/m2), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle (1H-MRS), and urinary carnosine levels were measured. Results Carnosine concentrations increased in urine after supplementation (P < 0.05). An increase in fasting insulin and insulin resistance was hampered in individuals receiving carnosine compared to placebo, and this remained significant after adjustment for age, sex, and change in body weight (P = 0.02, P = 0.04, respectively). Two-hour glucose and insulin were both lower after carnosine supplementation compared to placebo in individuals with impaired glucose tolerance (P < 0.05). Conclusions These pilot intervention data suggest that carnosine supplementation may be an effective strategy for prevention of type 2 diabetes.

Original languageEnglish
Pages (from-to)1027-1034
Number of pages8
JournalObesity
Volume24
Issue number5
DOIs
Publication statusPublished - 1 May 2016

Cite this

De Courten, B., Jakubova, M., De Courten, M. P. J., Kukurova, I. J., Vallova, S., Krumpolec, P., ... Ukropcova, B. (2016). Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. Obesity, 24(5), 1027-1034. https://doi.org/10.1002/oby.21434
De Courten, Barbora ; Jakubova, Michaela ; De Courten, Maximilian P J ; Kukurova, Ivica Just ; Vallova, Silvia ; Krumpolec, Patrik ; Valkovic, Ladislav ; Kurdiova, Timea ; Garzon, Davide ; Barbaresi, Silvia ; Teede, Helena J. ; Derave, Wim ; Krssak, Martin ; Aldini, Giancarlo ; Ukropec, Jozef ; Ukropcova, Barbara. / Effects of carnosine supplementation on glucose metabolism : Pilot clinical trial. In: Obesity. 2016 ; Vol. 24, No. 5. pp. 1027-1034.
@article{546b6e1bc35d40558d855ee03c38ffa8,
title = "Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial",
abstract = "Objective Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors. Methods In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 ± 8 years; body mass index 31 ± 4 kg/m2), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle (1H-MRS), and urinary carnosine levels were measured. Results Carnosine concentrations increased in urine after supplementation (P < 0.05). An increase in fasting insulin and insulin resistance was hampered in individuals receiving carnosine compared to placebo, and this remained significant after adjustment for age, sex, and change in body weight (P = 0.02, P = 0.04, respectively). Two-hour glucose and insulin were both lower after carnosine supplementation compared to placebo in individuals with impaired glucose tolerance (P < 0.05). Conclusions These pilot intervention data suggest that carnosine supplementation may be an effective strategy for prevention of type 2 diabetes.",
author = "{De Courten}, Barbora and Michaela Jakubova and {De Courten}, {Maximilian P J} and Kukurova, {Ivica Just} and Silvia Vallova and Patrik Krumpolec and Ladislav Valkovic and Timea Kurdiova and Davide Garzon and Silvia Barbaresi and Teede, {Helena J.} and Wim Derave and Martin Krssak and Giancarlo Aldini and Jozef Ukropec and Barbara Ukropcova",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/oby.21434",
language = "English",
volume = "24",
pages = "1027--1034",
journal = "Obesity",
issn = "1930-7381",
publisher = "Wiley-Blackwell",
number = "5",

}

De Courten, B, Jakubova, M, De Courten, MPJ, Kukurova, IJ, Vallova, S, Krumpolec, P, Valkovic, L, Kurdiova, T, Garzon, D, Barbaresi, S, Teede, HJ, Derave, W, Krssak, M, Aldini, G, Ukropec, J & Ukropcova, B 2016, 'Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial' Obesity, vol. 24, no. 5, pp. 1027-1034. https://doi.org/10.1002/oby.21434

Effects of carnosine supplementation on glucose metabolism : Pilot clinical trial. / De Courten, Barbora; Jakubova, Michaela; De Courten, Maximilian P J; Kukurova, Ivica Just; Vallova, Silvia; Krumpolec, Patrik; Valkovic, Ladislav; Kurdiova, Timea; Garzon, Davide; Barbaresi, Silvia; Teede, Helena J.; Derave, Wim; Krssak, Martin; Aldini, Giancarlo; Ukropec, Jozef; Ukropcova, Barbara.

In: Obesity, Vol. 24, No. 5, 01.05.2016, p. 1027-1034.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Effects of carnosine supplementation on glucose metabolism

T2 - Pilot clinical trial

AU - De Courten, Barbora

AU - Jakubova, Michaela

AU - De Courten, Maximilian P J

AU - Kukurova, Ivica Just

AU - Vallova, Silvia

AU - Krumpolec, Patrik

AU - Valkovic, Ladislav

AU - Kurdiova, Timea

AU - Garzon, Davide

AU - Barbaresi, Silvia

AU - Teede, Helena J.

AU - Derave, Wim

AU - Krssak, Martin

AU - Aldini, Giancarlo

AU - Ukropec, Jozef

AU - Ukropcova, Barbara

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors. Methods In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 ± 8 years; body mass index 31 ± 4 kg/m2), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle (1H-MRS), and urinary carnosine levels were measured. Results Carnosine concentrations increased in urine after supplementation (P < 0.05). An increase in fasting insulin and insulin resistance was hampered in individuals receiving carnosine compared to placebo, and this remained significant after adjustment for age, sex, and change in body weight (P = 0.02, P = 0.04, respectively). Two-hour glucose and insulin were both lower after carnosine supplementation compared to placebo in individuals with impaired glucose tolerance (P < 0.05). Conclusions These pilot intervention data suggest that carnosine supplementation may be an effective strategy for prevention of type 2 diabetes.

AB - Objective Carnosine is a naturally present dipeptide in humans and an over-the counter food additive. Evidence from animal studies supports the role for carnosine in the prevention and treatment of diabetes and cardiovascular disease, yet there is limited human data. This study investigated whether carnosine supplementation in individuals with overweight or obesity improves diabetes and cardiovascular risk factors. Methods In a double-blind randomized pilot trial in nondiabetic individuals with overweight and obesity (age 43 ± 8 years; body mass index 31 ± 4 kg/m2), 15 individuals were randomly assigned to 2 g carnosine daily and 15 individuals to placebo for 12 weeks. Insulin sensitivity and secretion, glucose tolerance (oral glucose tolerance test), blood pressure, plasma lipid profile, skeletal muscle (1H-MRS), and urinary carnosine levels were measured. Results Carnosine concentrations increased in urine after supplementation (P < 0.05). An increase in fasting insulin and insulin resistance was hampered in individuals receiving carnosine compared to placebo, and this remained significant after adjustment for age, sex, and change in body weight (P = 0.02, P = 0.04, respectively). Two-hour glucose and insulin were both lower after carnosine supplementation compared to placebo in individuals with impaired glucose tolerance (P < 0.05). Conclusions These pilot intervention data suggest that carnosine supplementation may be an effective strategy for prevention of type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84963611518&partnerID=8YFLogxK

U2 - 10.1002/oby.21434

DO - 10.1002/oby.21434

M3 - Article

VL - 24

SP - 1027

EP - 1034

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 5

ER -